BofA raised the firm’s price target on Hims & Hers to $32 from $28 and keeps an Underperform rating on the shares after the company reported a “mixed” quarter, with revenue and EBITDA exceeding Street and BofA estimates and total subscribers falling below expectations. The firm sees downside risk to 2026 consensus revenue estimates and lowered its own 2026 EBITDA estimates, but rolls its valuation framework from 2025 to 2026, yielding its increased price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Strong Buy Rating for Hims & Hers Health: Impressive Growth and Strategic Expansion Drive Future Potential
- Cautious Outlook Amid Strategic Expansion: Hold Rating for Hims & Hers Health
- Hims & Hers Stock (HIMS) Pops on Talks to Offer Novo Nordisk’s Wegovy
- Hims & Hers Health Reports Strong Q3 2025 Growth
- Closing Bell Movers: Palantir down 3% after earnings